Granules India Ltd. specializes in Pharmaceuticals within the Healthcare sector.
Granules India Ltd., with Security Code 532482, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Date Begin | Date End | Net Sales | Net Profit | Total Income | Diluted EPS for continuing operation | Other Expenses | Other Income | Depreciation and amortisation expense | Profit (+)/ Loss (-) from Ordinary Activities before Tax |
|---|---|---|---|---|---|---|---|---|---|
| 2024-01-01 | 2024-03-31 | 9,401.91 | 972.16 | 9,436.16 | 4.01 | -2,058.90 | 34.25 | -364.10 | 1,365.11 |
| 2023-10-01 | 2023-12-31 | 9,844.85 | 1,427.05 | 9,851.51 | 5.88 | - | 6.66 | -361.59 | 1,916.12 |
| 2023-10-01 | 2023-12-31 | 11,555.84 | 1,256.52 | 11,562.36 | 5.18 | - | 6.52 | -523.91 | 1,700.95 |
| 2023-07-01 | 2023-09-30 | 10,094.15 | 1,161.57 | 10,106.65 | 4.80 | -1,609.96 | 12.50 | -360.12 | 1,560.13 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 12% |
| 3 Years: | 6% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 22% |
| 3 Years: | -8% |
| TTM: | -13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 40% |
| 3 Years: | 16% |
| 1 Year: | 75% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 15% |
| 3 Years: | 12% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 11% |
| 3 Years: | -10% |
| TTM: | -22% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 40% |
| 3 Years: | 16% |
| 1 Year: | 75% |
Granules India on Thursday reported a 10 per cent rise in consolidated net profit to Rs 100.05 crore for the quarter ended December 31, 2022, mainly on account of higher revenue. The company had clocked a consolidated net profit of Rs 91.29 crore during the October-December quarter a year ago.
Granules India on Wednesday said it has received final approval from the US health regulator for its generic version of Pfizer's anti-infective drug Prezista (darunavir tablets). The company said it has received approval for strengths of 75 mg, 150 mg and 600 mg from the US Food and Drug Administration (USFDA).
Drug maker Granules India on Tuesday announced an investment of Rs 1,000 crore to set up a new active pharmaceutical ingredient (API) and formulations facility in Visakhapatnam, Andhra Pradesh. The company said the new facility will be spread across 100 acres and will be operational in two years.
